STRATA Skin Sciences (SSKN) Registration Filing summary

Company overview and business model

• Medical technology company focused on dermatology, developing and marketing products for treating skin conditions such as psoriasis, vitiligo, and acne.

• Key products include XTRAC excimer lasers, VTRAC lamp systems, and TheraClearX Acne Therapy System, with FDA clearances and international market presence.

• Incorporated in New York in 1989, reincorporated in Delaware in 1997, and currently headquartered in Horsham, Pennsylvania.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates is approximately $6.8 million as of November 13, 2024.

• 4,171,161 shares of common stock outstanding as of November 21, 2024; no preferred stock outstanding.

• During the prior 12 months, approximately $2.1 million in common stock sold under a previous Form S-3.

Use of proceeds and capital allocation

• Net proceeds intended for clinical and regulatory advancement, commercialization, potential acquisitions, and working capital.

• Management has broad discretion over timing and application of proceeds, with temporary investment in short-term, interest-bearing instruments pending use.